Associated Papers
Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.
Krebs K et al.
Npj Genomic Medicine, 2026
Whole-exome sequencing identified recurrent and novel variants in benzene-induced leukemia.
Lin D et al.
Bmc Medical Genomics, 2023
Recognition of functional genetic polymorphism using ESE motif definition: a conservative evolutionary approach to CYP2D6/CYP2C19 gene variants.
Samadi M et al.
Genetica, 2022
Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics.
Morales-Rosado JA et al.
Cardiovascular Drugs and Therapy, 2021
PharmVar GeneFocus: CYP2C19.
Botton MR et al.
Clinical Pharmacology and Therapeutics, 2021
Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children.
Espinoza N et al.
Scientific Reports, 2019
Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.
Hiratsuka M et al.
Drug Metabolism and Pharmacokinetics, 2018
Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
Novkovic M et al.
European Journal of Clinical Pharmacology, 2018
Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
Ng D et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.
Shirasaka Y et al.
The Pharmacogenomics Journal, 2016
Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.
Lim JS et al.
British Journal of Clinical Pharmacology, 2016
Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan.
Iskakova AN et al.
Bmc Genetics, 2016
Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation.
Takahashi M et al.
The Pharmacogenomics Journal, 2015
Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.
Scott SA et al.
The Pharmacogenomics Journal, 2012
Recent advances in the pharmacogenetics of clopidogrel.
Cuisset T et al.
Human Genetics, 2012
Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.
Helsby NA et al.
Frontiers in Genetics, 2012
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.
Wang H et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2011
Role of cytochrome P450 genotype in the steps toward personalized drug therapy.
Cavallari LH et al.
Pharmacogenomics and Personalized Medicine, 2011
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2010
Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.
Zhou Q et al.
The Pharmacogenomics Journal, 2009
Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole.
Lee SJ et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population.
Hanioka N et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2007
The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives.
Sim SC et al.
Methods in Molecular Biology (clifton, N.j.), 2006
The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH et al.
Journal of Human Genetics, 2006
Identification and functional characterization of new potentially defective alleles of human CYP2C19.
Blaisdell J et al.
Pharmacogenetics, 2002
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.
Goldstein JA
British Journal of Clinical Pharmacology, 2001
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.
Ibeanu GC et al.
The Journal of Pharmacology and Experimental Therapeutics, 1998
The Human Cytochrome P450 Allele Nomenclature Committee Web Site : Submission Criteria, Procedures, and Objectives.
Sim SC et al.
Methods in Molecular Biology (clifton, N.j.), 0